ROCHESTER, NY--(Marketwire - Oct 9, 2012) - NaturalNano, Inc. (OTCBB: NNAN) today announced that an online video featuring NaturalNano's Halloysite Nanotubes (HNT) is available. The video demonstrates work done in the laboratories of Dr. Michael King at Cornell University in Ithaca, NY on a device containing HNTs that separated and captures circulating tumor cells (CTCs) contained in human blood.
Dr. King, an associate professor of Biomedical Engineering at Cornell University, is an expert on fluid dynamics and the techniques to separate target cells from blood. His video can be viewed at a scientific web site: http://www.jove.com/video/4248. Dr. King states, "We found that the efficiency of our device methodology for the separation and capture of CTCs from blood samples is significantly improved by the use of surfaces with a thin coating of Halloysite Nanotubes."
James Wemett, NaturalNano CEO, said, "We are very excited to have our HNT featured in Dr. King's important video." Wemett continued, "We now are offering for sale on the NaturalNano website (www.naturalnano.com) sample kits of HNT for experimental use by researchers for other Life Science applications."
NaturalNano, Inc. (OTCBB: NNAN) is a materials science company focused on developing and commercializing advanced nanocomposites. The Company is focused on additive technologies and processes, including its proprietary Pleximer that adds value to industrial polymers, plastics and composites. NaturalNano holds and/or licenses 20 patents and applications relating to Halloysite, as well as proprietary know-how for its extraction and separation processes, compositions, and derivatives. www.naturalnano.com
Cautionary Statement Regarding Forward-Looking Statements: Contains forward-looking statements regarding future events and future performance that involve risks and uncertainties that could materially affect actual results. This information is qualified in its entirety by cautionary statements and risk factors disclosure contained in certain of NaturalNano's filings with the Securities and Exchange Commission. The most recent annual reports on Form 10-K and quarterly reports on Form 10-Q filed by NaturalNano provide information about these factors, which may be revised or supplemented in future reports to the SEC on those forms or on Form 8-K. We caution investors not to place undue reliance on forward-looking statements, and we do not undertake any obligation to update or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other such factors that affect the subject of these statements, except where expressly required by law.